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Purpose: The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients 
with primary osteoporosis have not been well established.
Methods: We searched MedLine, EMBase, CENTRAL, CINAHL, and AgeLine prior to 
  February 2010. Bibliographies were also searched and experts in the field contacted. The 
  ProQuest Dissertations and Theses database and relevant conference proceedings were searched 
to identify unpublished or ongoing studies. Two authors independently reviewed search results. 
Randomized controlled trials and comparative nonrandomized controlled trials examining post-
menopausal women or men $50 years of age with primary osteoporosis assigned to continue 
versus discontinue bisphosphonate therapy after $5 years of therapy were included. Of 1188 
identified articles, three studies (n = 1443) met criteria for inclusion in data synthesis. Data were 
extracted and risk of bias assessed by two independent reviewers using predefined criteria.
Results: No statistically significant association was found between fracture incidence and 
the discontinuation of therapy beyond 5 years for any type of fracture: clinical nonvertebral 
fracture (relative risk [RR] = 0.97; 95% confidence interval [CI] 0.77–1.23), clinical vertebral 
fracture (RR = 0.61; 95% CI 0.32–1.19), or morphometric vertebral fracture (RR = 0.90; 95% 
CI 0.5–1.64). No differences in adverse events were identified between the two groups.
Conclusion: We found no significant difference in fracture risk or adverse events between 
postmenopausal women with primary osteoporosis who continued bisphosphonate therapy versus 
those who discontinued bisphosphonate therapy after 5 years of treatment. However, given the 
small number and limited quality of available studies, no firm conclusions or recommendations 
can be made.
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Introduction
Osteoporosis is a common condition in Canada, affecting up to 1 in 4 women 
and 1 in 8 men, with numbers expected to rise as the population ages.1 Currently, 
bisphosphonates are considered first-line therapy for both prevention and treatment 
of osteoporosis in men and postmenopausal women.2,3 Multiple studies support the 
efficacy of bisphosphonate therapy in preventing bone loss and decreasing fracture 
risk for up to 4 years of treatment, but few studies have examined the effects of 
bisphosphonate therapy beyond 5 years.4,5
Bisphosphonates work by inhibiting bone resorption and decreasing bone formation. 
Unlike other medications, bisphosphonates remain in bone for long periods of time Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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after therapy is discontinued, with a calculated elimination 
half-life for some bisphosphonates of up to 10 years.6 
With continued use, the amount of drug deposited in bone 
accumulates.7 Therefore, it is thought that the actions of 
bisphosphonates may continue for some time after they have 
been discontinued, as they are slowly released from bone 
during bone turnover.8 There has been some concern about 
the cumulative effect of prolonged bisphosphonate use on 
bone integrity.7 With continued increased mineralization, 
bone may become brittle and fracture risk may increase. 
Although causality has not been established, multiple 
reports of unexpected, low-energy subtrochanteric fractures 
in patients on prolonged bisphosphonate (alendronate) 
therapy have made many clinicians question the wisdom of 
suppressing bone turnover with bisphosphonates for extended 
periods of time, as it may lead to decreased repair of bone 
microdamage and an increased risk of stress fractures.9–11 
Other potential, but serious, adverse effects associated with 
bisphosphonate therapy include osteonecrosis of the jaw and 
a possible link to increased rates of atrial fibrillation.12,13
Few studies have examined the effects of bisphosphonate 
therapy beyond 5 years, leaving many clinicians questioning 
what the next most appropriate step is. Osteoporotic fractures 
cause significant morbidity and mortality. Hip fracture leads 
to nursing home placement in approximately 58% of patients, 
and death, within 1 year of fracture, occurs in 22%–29% 
of patients.14,15 Hence, identifying the optimal course of 
bisphosphonate treatment for patients with osteoporosis, 
while avoiding needless (and potentially dangerous) over-
treatment, is of utmost importance.
We performed a systematic review to examine whether 
continuing bisphosphonates after 5 years of therapy for 
primary osteoporosis is associated with a decreased fracture 
risk, increased bone mineral density (BMD), decreased rates 
of bone turnover, and increased mortality and adverse events 
compared with similar individuals who discontinue therapy. 
Our goal was to include all published randomized controlled 
trials and nonrandomized controlled trials that measured 
the effect of long-term (beyond 5 years) bisphosphonate 
therapy used for the prevention and treatment of primary 
osteoporosis on vertebral (clinical and morphometric) 
and nonvertebral fractures or BMD. No prior systematic 
reviews have been performed on this topic. We aim, by 
summarizing the current available literature, to define the 
risks and benefits of continuation versus discontinuation 
of therapy after 5 years and to identify areas where future 
research is needed.
Methods
eligibility criteria
All clinical trials (randomized and nonrandomized) examining 
discontinuation of bisphosphonate therapy in patients with 
primary osteoporosis after $5 years of treatment were 
included. No language, publication date, or publication 
status restrictions were imposed. Postmenopausal women 
and men $50 years of age with primary osteoporosis were 
included. Osteoporosis was defined as a pretreatment BMD 
T-score of #−2.5 at either the hip or spine, or a minimal trauma 
fracture occurring after the age of 45 years. Participants who 
started another osteoporosis medication after discontinuing 
their bisphosphonate (selective estrogen receptor modulator, 
calcitonin, hormone replacement therapy, teriparatide) 
were excluded. We included all types of bisphosphonates 
regardless of mode of administration (intravenous or oral) 
or dose. The primary outcome measure for this review 
was fragility fracture (both clinical and morphometric). 
Secondary outcomes included change in BMD (at any site), 
change in bone turnover markers, mortality, and adverse 
events. All adverse events were included, but particular 
attention was paid to osteonecrosis of the jaw, new atrial 
fibrillation, renal dysfunction, subtrochanteric fractures, 
and gastrointestinal events. Studies included in the review 
had to have a minimal length of follow-up of 1 year after 
discontinuation of bisphosphonate therapy.
information sources and search
An electronic search was conducted using the following 
electronic databases (date of search: February 8, 2010): 
OVID MedLine (1950–2010 week 3), OVID EMBase (1980–
2010 week 4), the Cochrane Central Register of Controlled 
Trials (CENTRAL), CSA-AgeLine (1978–present), and the 
Cumulative Index to Nursing and Allied Health Literature 
(EBSCO-CINAHL) (1982–present). To review potentially 
relevant grey literature, the ProQuest Dissertations and 
Theses database was searched and conference proceedings 
from the International Osteoporosis Foundation (IOF) and 
American Society of Bone Mineral Research (ASBMR) for 
the past 3 years were hand searched. Studies identified as 
relevant during the review were cross-referenced for relevant 
citations. Experts in the field were contacted for relevant 
citations and unpublished or ongoing studies. Keywords 
and search strategies were reviewed by a research librarian   
who is experienced in systematic reviews of healthcare 
literature. Variations in search terms were used in different 
databases to reflect the differences in indexing used by Therapeutics and Clinical Risk Management 2011:7
Additional articles
identified (n = 3) 
Full text articles excluded
(n = 27) 
2 subjects did not have
osteoporosis
10 not on bisphosphonate
for ¥ 5 years
4 no group discontinued
bisphosphonate therapy
3 no group continued
treatment
3 duplicate publication
5 nonexperimental study
(editorial, review, observational
study)
Excluded articles
(n = 1158)
Articles identified in
database search (n = 1560)
Articles screened (after
duplicates removed)
(n = 1188)
Articles selected for full
text review (n = 30)
Articles included in review
(n = 3)
Articles included in
meta-analysis (n = 3)
Figure 1 Flow diagram of study selection.
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different databases. The full search strategy used in OVID 
MedLine is presented in Appendix 1.
study selection and data collection
Two reviewers independently screened all titles and abstracts 
retrieved from searching. Agreement between the two 
reviewers for this initial screen was fair (κ statistic = 0.44 
[95% confidence interval (CI) 0.33–0.55]). Any titles or 
abstracts deemed to be potentially relevant by either reviewer 
were then reviewed independently in full text form by both 
reviewers using predefined inclusion criteria. There was 
perfect agreement between the two reviewers during full text 
screening (κ statistic = 1.0). Data were then independently 
abstracted by each reviewer using a single comprehensive 
data extraction form. In studies with multiple reports, all 
prior publications were collected and integrated with the final 
report to make the data available for extraction as complete 
as possible. Disagreements were resolved by consensus.
The two reviewers also independently assessed each 
eligible study for risk of bias during the data extraction 
phase using the Cochrane “risk of bias tool”.16 Inter-rater 
agreement was calculated by means of κ statistics for each 
of the six items in the tool (sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective 
outcome reporting, and other bias).
summary measures and synthesis
Relative risk (RR) of fracture was the primary measure of 
treatment effect. For all dichotomous outcomes (fracture, 
mortality, and adverse events), RR and 95% CI were 
calculated using the Mantel–Haenszel method. For continu-
ous outcomes (BMD and bone turnover markers) we planned 
to calculate mean difference and standard error using the 
generic inverse variance method. Random effects models 
were used for all calculations to account for between-study 
variability. All calculations were performed using RevMan 
5 software (The Nordic Cochrane Centre, Copenhagen, 
Denmark).
In trials where discontinuation (placebo) was compared 
with more than one dose of bisphosphonate continuation, 
the different dose groups were combined to create a 
single comparison (where sufficient data were available) 
of continuation (bisphosphonate) versus discontinuation 
(placebo). Similarly, different trials examining different 
bisphosphonates were included in the analysis. Sensitivity 
and subgroup analyses were planned a priori to explore excess 
heterogeneity that this combining of trials may cause. Where 
not stated by trial authors, numbers of events per group were 
calculated from percentage of events per group and number 
of patients per group. Only studies that reported a specified 
outcome were included for that particular effect estimate. We 
tested for heterogeneity by calculating a test of heterogeneity 
and an I2 statistic. We hypothesized a priori that possible 
causes of heterogeneity of study results would include type of 
bisphosphonate used, severity of osteoporosis in trial subjects, 
male versus female subjects, duration of bisphosphonate 
use before discontinuation, length of follow-up, and quality 
of trials. Subgroup analyses were planned a priori for these 
variables. We planned to use funnel plots for each outcome to 
assess for risk of publication bias based on plot asymmetry. 
Broad search inclusion criteria and examination of grey 
literature during the search phase of this review were meant 
to decrease bias in our results. Both data abstractors attempted 
to estimate reporting bias in individual studies.
Results
Figure 1 shows the flow of studies selected for this review. 
After duplicate studies were removed, 1188 studies (from 
all sources) were included in the title and abstract screening. 
Of those, 1158 studies were identified as being irrelevant 
or inappropriate to our review topic and therefore were 
excluded. The remaining 30 studies were included in formal 
full text review. Three studies met inclusion criteria and were 
included in the systematic review and meta-analysis.
The three included studies were all extension studies of 
prior randomized controlled trials. For the FLEX (Fracture 
Intervention Trial Long Term Extension) 1996 study (Black 
et al17) and the 1997 study by Miller et al,18 participants 
were rerandomized into bisphosphonate (continuation) Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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versus placebo (discontinuation) groups after a mean of 
5 years of bisphosphonate therapy. In contrast, in the 2004 
study by Bone et al,19 subjects were not rerandomized after 
5 years of bisphosphonate therapy but remained in their 
original randomized groups with one group changed from 
bisphosphonate to placebo at year 5. A summary of study 
characteristics is presented in Table 1.
study characteristics
Participants
The included studies involved 1443 postmenopausal women 
of different ethnicities mostly from the US. A total of 877 
women were assigned to the continuation of bisphospho-
nate group and 566 women were in the discontinuation 
(placebo) group. However, for the outcome clinical vertebral 
fractures, results were not available in the Bone et al19 study 
and therefore an earlier published extension study of this 
same cohort was used, which included slightly more patients, 
thereby inflating the total number of participants for this 
one outcome.20 Included women were postmenopausal and 
generally had primary osteoporosis, defined either by a his-
tory of fragility fracture or a BMD T-score of ,−2.5, at the 
start of the original drug study (ie, not at the beginning of the 
extension study). The exception was the FLEX trial,17 which 
included women with a femoral neck BMD of ,0.68 g/cm2 
as part of the original study inclusion criteria.21 Mean age of 
participants in the three studies was between 63 years and 
74 years. All subjects received 500 mg of calcium per day, 
Table 1 Characteristics of included studies
Study Participants Intervention Outcomes Methodological  
quality
Notes
Black et al17 1099 postmenopausal women 
from the Us, originally with  
BMD # 0.68 g/cm2, who  
received alendronate  
5 mg/day for 2 years and then  
10 mg/day for a total mean  
duration of therapy of 5 years’  
treatment during the Fracture  
intervention Trial 
Alendronate 5 mg/day 
(n = 329) or  
10 mg/day (n = 333)  
vs placebo (n = 437)  
for 5 years
Change in BMD at  
hip and other sites 
Changes in bone 
turnover markers 
Fracture incidencea 
Outcomes measured  
at 5-year follow-up
As adequately generated 
AC not clear 
Blinding: patients, 
physicians, data  
collectors, and  
outcome assessors 
incomplete data  
adequately addressed 
no selective outcome 
reporting, or other  
threats to validity
Funded by Merck 
and Co. (makers of 
alendronate, the study 
drug) 
Merck involved with 
study design, editorial 
input, and approval  
of final manuscript 
not all participants 
had “osteoporosis” 
by WHO definition, 
inclusion criterion  
was BMD # 0.68 g/cm2
Bone et al19 804 postmenopausal women  
from multiple countries with  
BMD T-scores ,−2.5  
underwent initial  
randomization;  
247 included in the year  
8–10 extension study  
(used for this review)
Alendronate 5 mg/day 
(n = 78) vs 10 mg/day 
(n = 86) for 10 yrs vs 
20 mg/day for 2 years 
then 5 mg/day for  
3 years then placebo  
for 5 years (n = 83)
Change in BMD at 
lumbar spine and  
other sites 
Changes in bone 
turnover markers 
Morphometric and 
clinical vertebral 
fracture incidenceb 
height change 
safety 
Outcomes measured  
at either 2- or  
5-year follow-up
As and AC not clear 
“Double blinded”, also  
data assessors blinded 
incomplete data not 
adequately addressed 
All outcomes not fully 
reported
no other threats  
to validity
Funded by Merck 
Research Laboratories 
(makers of alendronate, 
the study drug)
First author with 
honorariums and 
grant support from 
Merck
Miller et al18 97 postmenopausal women  
from the Us with a history  
of fragility fracture completed 
7 years of follow-up with  
at least 5 years of etidronate  
therapy
Continued cyclical 
etidronate (n = 51) 
vs placebo (n = 46) 
(subgroups of larger 
extension study)
Change in BMD at 
lumbar spine and  
other sites
Morphometric 
vertebral fracture 
incidence
safety
Outcomes measured  
at 2-year follow-up
As adequately generated 
AC not clear 
“Double blinded” 
incomplete data not 
adequately addressed 
All outcomes not fully 
reported 
no other threats  
to validity
Funded by Procter 
and gamble 
Pharmaceuticals 
(makers of etidronate, 
the study drug)
Notes: aFracture incidence was considered an exploratory outcome; bFracture incidence collected as safety endpoint, no formal analysis planned. no attempt made to 
exclude trauma-related fractures.
Abbreviations: AC, allocation concealment; As, allocation sequence; BMD, bone mineral density; WhO, World health Organization.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and the FLEX trial also offered 250 IU of vitamin D to both 
treatment groups.
interventions
All trials included participants who had been on bisphos-
phonate therapy for a mean of 5 years. The Bone et al19 and 
Miller et al18 trials studied other groups of patients as well, but 
for the purposes of this systematic review these other groups 
were not examined. In the “continuation” group in the FLEX17 
and Bone et al trials, participants were divided into two 
subgroups (5 mg or 10 mg per day of oral alendronate). The 
Miller et al trial looked at 90- to 91-day cycles of etidronate 
400 mg per day for 14 days followed by 500 mg of elemental 
calcium per day. A placebo was given to the “discontinuation” 
group in all trials. The Bone et al and FLEX trials reported 
outcomes at 5 years after discontinuation (or continuation) 
of alendronate therapy, whereas the Miller et al trial reported 
outcomes at 2 years.
Outcomes
The primary outcome in the Miller et al18 and Bone et al19 
studies was percentage change in lumbar spine BMD; in 
FLEX17 it was change in total hip BMD. BMD was analyzed 
on an intention-to-treat (or “modified” intention-to-treat) 
basis in the FLEX and Bone et al studies. Loss to follow-up 
was dealt with by carrying forward the last known value. 
Changes in bone turnover markers were analyzed on a per 
protocol basis in both these studies, and none of the three 
studies stated clearly how fracture data were assessed. All 
studies reported adverse events. Change in bone turnover 
markers was included as a secondary outcome in the FLEX 
and Bone et al trials. Fracture was not a primary outcome 
in any trial.
Risk of bias
Specific components of methodological quality are listed 
in Table 1. All three studies were sponsored by the drug 
company making the bisphosphonate used in the study, and 
therefore potential conflict of interest existed in all cases.
Outcomes
Fracture
The forest plots presented in Figure 2 (panels a, b, and c) 
show trial-level fracture rates for nonvertebral, clinical 
vertebral, and morphometric vertebral fractures in bispho-
sphonate continuation and discontinuation groups. Hip 
fracture rates were also reported in the FLEX trial with 
RR 1.02 (95% CI 0.51–2.10) in the continuation group 
(20 of 662 patients) versus discontinuation group (13 of 
437 patients).
Two trials reported rates of clinical nonvertebral fractures 
at 5 years. The pooled analysis showed no difference in 
rates between the continuation and discontinuation groups 
(RR = 0.91, 95% CI 0.77–1.23, I2 = 0%). Pooled analysis 
of the same two trials showed that rates of clinical vertebral 
fractures were no different between groups (RR = 0.61, 95% 
CI 0.32–2.09, I2 = 41%). However, for this outcome, results 
for one study were reported from 2-year follow-up, whereas 
the other was 5-year follow-up, which may contribute to 
the higher I2 value, although the results were not found to 
be heterogeneous (χ2 = 1.68, degree of freedom [df] = 1, 
P = 0.19). It should be noted that before pooling, the Black 
et al17 study did show a significant increase in clinical 
vertebral fractures in those discontinuing bisphosphonate 
therapy after 5 years. However, this result became statistically 
nonsignificant when pooled. Morphometric vertebral frac-
tures were reported in all three studies. However, results from 
Miller et al18 were reported at 2-year follow-up, whereas the 
results from the other two trials were from 5-year follow-up. 
Pooled analyses showed no difference between groups 
(RR = 0.9, 95% CI 0.5–1.64, I2 = 31%).
Change in BMD
Although all three trials reported change in BMD as their 
primary outcome, the number of subjects analyzed and the 
standard deviation for each outcome was not provided in two 
of the three studies, and therefore results were not able to be 
pooled. As seen in Table 2, bone gain was consistently higher 
(or bone loss was less) in the continuation group compared 
with in the discontinuation group at all sites (lumbar spine, 
femoral neck, and trochanter) in all three studies. Two of the 
studies did not perform direct between-group comparisons, 
and therefore statistical significance is not stated. However, 
comparisons were performed in the reporting of the FLEX 
trial with decreased BMD in the discontinuation (versus 
continuation) group of −2.4% for total hip (P , 0.001) and 
−3.7% for the lumbar spine (P , 0.001), indicating that 
significant losses in BMD do occur in patients discontinuing 
bisphosphonate therapy after 5 years.
Change in bone turnover markers
Change in bone turnover markers from the time of 
  continuation/discontinuation to 5-year follow-up were not 
described in the reports from Bone et al19 (only shown graphi-
cally) or Miller et al.18 In a select subset of FLEX17 patients 
(n = 236), increased bone turnover was found 5 years later in Therapeutics and Clinical Risk Management 2011:7
a. Clinical nonvertebral fractures 
Study or Subgroup
Black 2006
Bone 2004
Total (95% CI)
Total events
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Events
125
16
141
Total
662
164
826
Events
83
10
93
Total
437
83
520
Weight
88.3%
11.7%
100.0%
M-H, Fixed, 95% CI
0.99 [0.77, 1.28]
0.81 [0.38, 1.71]
0.97 [0.77, 1.23]
M-H, Fixed, 95% CI
Favors continuation
b. Clinical vertebral fractures 
Study or Subgroup
Black 2006
Bone 2004
Total (95% CI)
Total events
Heterogeneity: Tau2 = 0.10; Chi2 = 1.68, df = 1 (P = 0.19); I2 = 41%
Test for overall effect: Z = 1.44 (P = 0.15)
Events
16
15
31
Total
662
234
896
Events
23
8
31
Total
437
114
551
Weight
58.1%
41.9%
100.0%
M-H, Random, 95% CI
0.46 [0.25, 0.86]
0.91 [0.40, 2.09]
0.61 [0.32, 1.19]
M-H, Random, 95% CI
c. Morphometric vertebral fractures 
Study or Subgroup
Black 2006
Bone 2004
Miller 1997
Total (95% CI)
Total events
Heterogeneity: Tau2 = 0.10; Chi2 = 2.89, df = 2 (P = 0.24); I2 = 31%
Test for overall effect: Z = 0.33 (P = 0.74)
Events
60
15
1
76
Total
662
164
42
868
Events
46
5
5
56
Total
437
83
46
566
Weight
66.6%
26.1%
7.3%
100.0%
M-H, Random, 95% CI
0.86 [0.60, 1.24]
1.52 [0.57, 4.03]
0.22 [0.03, 1.80]
0.90 [0.50, 1.64]
M-H, Random, 95% CI
d. Mortality 
Study or Subgroup
Black 2006
Bone 2004
Total (95% CI)
Total events
Heterogeneity: Tau2 = 0.78; Chi2 = 1.68, df = 1 (P = 0.20); I2 = 40%
Test for overall effect: Z = 0.03 (P = 0.97)
Events
19
4
23
Total
662
164
826
Events
19
0
19
Total
437
83
520
Weight
77.2%
22.8%
100.0%
M-H, Random, 95% CI
0.66 [0.35, 1.23]
4.58 [0.25, 84.10]
1.03 [0.20, 5.18]
Risk ratio Risk ratio Discontinuation Continuation
Risk ratio Risk ratio Discontinuation Continuation
Risk ratio Risk ratio Discontinuation Continuation
Risk ratio Risk ratio Discontinuation Continuation
M-H, Random, 95% CI
0.01 0.1110 100
0.01 0.1110 100
0.01 0.1110 100
0.01 0.1110 100
Favors discontinuation
Favors continuation Favors discontinuation
Favors continuation Favors discontinuation
Favors continuation Favors discontinuation
Figure 2 Forest plots showing pooled estimates for fracture risk and mortality in patients who continue bisphosphonates after 5 years of therapy versus those who 
discontinue after 5 years.
Notes: aClinical nonvertebral fractures; bClinical vertebral fractures; cMorphometric vertebral fractures; dMortality.
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those discontinuing bisphosphonate therapy compared with 
those continuing therapy. Markers were elevated by 55.6% 
(P , 0.001) for c-telopeptide of type 1 collagen, 59.5% 
(P , 0.001) for serum n-propeptide of type 1 collagen, and 
28.1% (P , 0.001) for bone-specific alkaline phosphatase.
Mortality
Two of the three studies reported death rates. Pooled 
analysis showed no difference between discontinuation and 
continuation groups (RR = 1.03, 95% CI 0.2–5.18, I2 = 40%) 
Heterogeneity χ2 = 1.68, df = 1, P = 0.20. A wide confidence 
interval is probably the result of very small numbers of 
reported deaths in all groups.
Adverse effects
All three studies comment that no significant differ-
ences in adverse events were found between treatment 
and placebo groups. Numerical comparisons of specific Therapeutics and Clinical Risk Management 2011:7
Table 2 Mean percentage change (standard error) in bone mineral density over 5 years in continuation versus discontinuation of 
bisphosphonate groups
Trial Continuation/discontinuation Lumbar spine Femoral neck Trochanter
Alendronate
Black et al17  
(FLeX)
Continuation 5.26 (0.24) 0.46 (0.24) −0.08 (0.22)
Discontinuation 1.52 (0.29) −1.48 (0.30) −3.25 (0.27)
Alendronate
Bone et al19,a Continuation
  5 mg group 2.5 (0.56) 1.0 (0.87) 0.0 (0.87)
  10 mg group 3.7 (0.56) 0.9 (0.87) 1.0 (0.82)
Discontinuation 0.3 (0.61) −2.2 (0.87) −1.0 (0.82)
Etidronate
Miller et al18,b Continuation 1.8 (0.71) 0.5 (0.82) 0.4 (0.76)
Discontinuation 1.4 (1.11) −0.9 (0.96) −0.6 (0.91)
Notes: aNo combined continuation group data available. Standard error calculated from confidence intervals provided in paper; bResults are from 2-year follow-up.
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adverse events between groups were not reported for 
most outcomes.
Risk of bias across studies
Due to the small number of studies included in our review, 
funnel plots were not appropriate or helpful. Although none 
of the outcomes demonstrated statistical heterogeneity, all 
outcomes should be viewed with caution, given the small 
sample size. Similarly, with the very small number of studies 
included in this review, prespecified subgroup analyses were 
not able to be performed. Results from the Miller et al18 
trial, in particular, were suspected of being different from 
the other studies, as Miller et al reported outcomes after 
2 years of bisphosphonate discontinuation (versus 5 years in 
the other trials) and studied etidronate (versus alendronate 
in the other trials). The only pooled fracture result that 
included the Miller et al study was that of morphometric 
fracture. A   sensitivity analysis was therefore performed, with 
the Miller et al study removed. The RR of morphometric 
vertebral fracture was found to be 0.95 (95% CI 0.62–1.44, 
I2 = 12%), which was a minimally changed effect estimate.
Discussion
This systematic review found no difference in fracture 
incidences in patients with primary osteoporosis who 
continued bisphosphonate therapy for an additional 2–5 years 
versus those who discontinued treatment at 5 years. Incidence 
of nonvertebral fractures, clinical vertebral fractures, and 
morphometric vertebral fractures were all found to be 
similar in the two groups. However, the evidence presented 
here is not robust enough to make definitive conclusions, 
due to the small number of studies: three studies including 
1443 patients (1447 for clinical vertebral fractures) with 
only one to two studies with available data for meta-analysis 
for most outcomes. Also, all three trials were sponsored 
by the pharmaceutical company that manufactures the 
bisphosphonate under study in the trial, resulting in the 
possibility of a significant conflict of interest.
None of the three trials sought to examine fracture 
incidence as a primary outcome, probably due to the fact 
that all three trials were designed as follow-ups to larger 
trials. These extensions were designed to look at the effects 
over time on BMD and bone markers and were not powered 
to look at fracture risk. All fracture-related data were 
therefore either exploratory or considered together with 
safety outcomes. Pooled fracture effect estimates presented 
here had wide confidence intervals, and all crossed 0, 
indicating that the true effect of continued bisphosphonate 
therapy could be negligible or, in many cases, could provide 
significant benefit or significant harm. No differences in 
adverse effects or mortality were identified between the 
two groups. Specifically, there were no reported cases of 
subtrochanteric fractures, osteonecrosis of the jaw, or atrial 
fibrillation (the most common reasons for concern with 
long-term bisphosphonate use). However, whether these 
events were not specifically looked for, or whether the 
number of subjects was just too small to capture them, is   
unclear.
Although we were unable to pool BMD results, all three 
trials showed a clear trend toward ongoing BMD gain (or 
less BMD loss) in groups where bisphosphonate therapy 
was continued. These BMD differences were found to 
be significant in the FLEX trial. Similarly, in a subset of 
subjects studied in the FLEX trial, bone turnover markers 
were elevated 5 years after discontinuation of alendronate 
compared with levels in those who continued alendronate.
Studies included in this review examined postmenopausal 
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fracture before initiation of bisphosphonate therapy. 
Therefore, findings cannot be applied to individuals 
outside these criteria. Similarly, conclusions in patients 
taking bisphosphonate therapies other than aldendronate 
or   etitdronate cannot be assumed. In particular, zoledronic 
acid, which is the most potent bisphosphonate available and 
the longest lasting, may have different effects on long-term 
fracture risk after discontinuation.22
We found no effect on fracture risk after discontinuation of 
bisphosphonate therapy after 5 years of treatment. However, 
treatment for a shorter interval followed by discontinuation 
may result in different risks as bisphosphonates have less 
time to accumulate in bone. Previous studies have shown 
that residual BMD benefits after treatment withdrawal are 
proportional to the original duration of bisphosphonate 
therapy.23,24 Similarly, the studies in this review followed 
patients for a maximum of 5 years after discontinuation. The 
implications of discontinuation beyond this 5-year follow-up 
period are unknown.
Strengths of this review include the rigorous search 
strategy used to identify articles. All study selection and 
data abstraction were performed in duplicate in order to 
minimize errors and bias, and excellent agreement was 
found between reviewers. Similarly, quality of studies was 
assessed in duplicate using a formal “risk of bias” tool, with 
excellent agreement.
As mentioned previously, the quality and volume of the 
evidence retrieved limit its interpretation. We were also 
limited by the reporting of included trials. For instance, some 
outcome data (eg, bone turnover markers) were reported in 
graphical format only in some studies, and we were unable 
to obtain the original trial data to incorporate into our meta-
analysis. Another limitation is that studies varied in terms 
of bisphosphonate type and dose used in the 5 years prior to 
discontinuation. Given the different half-life properties of 
different bisphosphonates, this may affect bone-protective 
properties after discontinuation. This also limits applicability 
of results to current clinical practice where once-weekly (or 
once-monthly) oral bisphosphonate preparations are standard 
and etidronate therapy is generally no longer considered a 
first-line therapy.3,25
No previous systematic reviews have been carried out on 
this particular topic, but multiple narrative summaries and 
editorials have been written. It has been suggested, based 
on the limited amount of data available in this area, that 
all patients should have their fracture risk reassessed after 
5 years of therapy to see whether ongoing treatment with 
bisphosphonate therapy is warranted. Continuing therapy 
may be appropriate in those who continue to be at high risk, 
whereas discontinuing treatment may be more appropriate 
in lower-risk patients.26 This is similar to the conclusions 
offered by the authors of the FLEX trial, who suggested 
that women at very high risk of clinical vertebral fractures 
continue therapy, whereas in other women discontinuation 
does not increase fracture risk.17 Our study adds support to 
those who argue that there is currently no proof that continued 
bisphosphonate therapy beyond 5 years has any effect on 
fracture outcomes.27,28 Similar to our study, other papers 
have questioned the fracture results of current randomized 
controlled trials citing insufficient power and significant 
loss to follow-up in these trials.29 Thus, in general, most 
of the literature to date comments on the lack of current 
antifracture evidence in this area and the need for further 
studies. The findings of our review are in keeping with these 
comments.
Conclusion
implications for practice
Between 1997 and 2006, extension studies of three 
randomized controlled trials looked at the impact of 
continuation versus discontinuation of bisphosphonate 
therapy after 5 years of treatment in postmenopausal women 
with primary osteoporosis. All three trials found improved 
BMD with continuation of bisphosphonate therapy and, when 
it was examined, increased suppression of bone turnover 
markers. None of the trials found excess burden of continued 
long-term bisphosphonates in terms of extra adverse events 
or mortality. However, BMD and bone turnover markers are 
surrogate outcomes, and when pooled data were examined, 
the patient-important outcome of fracture risk was found to 
be no different between the continuation and discontinuation 
groups. Due to the small number and limited quality of 
included studies as well as differences in treatment provided 
(compared with that routinely used in current clinical 
practice), no firm conclusions or recommendations can 
be made.
implications for research
This review highlights the importance, and urgency, of further 
research in this area. Considering how common osteoporosis 
is in the general population and that bisphosphonate therapy 
is considered first-line treatment, it is imperative that we be 
able to offer clinicians clear, evidence-based guidance on 
how to manage bisphosphonate therapy in the long term 
(beyond 5 years). Randomized controlled trials, using current 
modes of bisphosphonate therapy and specifically powered Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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for fracture outcome, need to be performed. Similarly, to 
inform policy makers, cost-effectiveness studies looking at 
treatment beyond 5 years need to be performed.
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Appendix 1 OViD MedLine search strategy (1950 to January week 4 2010)
No. Searches Results
1 Osteoporosis/ 27,944
2 Osteoporosis, Postmenopausal/ 8648
3 Osteoporosis.mp. 45,270
4 1 or 2 or 3 45,270
5 Bisphosphonate$.mp. 6888
6 Diphosphonates/or alendronate/or clodronic acid/or etidronic acid/ 12,926
7 Alendronate.mp. 2624
8 Risedronate.mp. 838
9 Pamidronate.mp. 2175
10 Zoledronic acid.mp. 1348
11 etidronate.mp. 1048
12 ibandronate.mp. 487
13 Diphosphonate$.mp. 11,655
14 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 16,843
15 4 and 14 5044
16 Time factors/ 830,953
17 Follow-up studies/ 393,252
18 Follow up studie$.mp. 397,885
19 (stop$ or hold$ or finish$ or withold$ or withdraw$ or withdrew$ or drug holiday$ or skip$ or halt$ or 
cessat$ or discontinue$ or held or cease$ or suspend$).mp. [mp = title, original title, abstract, name of 
substance word, subject heading word, unique identifier]
391,767
20 16 or 17 or 18 or 19 1,512,880
21 15 and 20 836
22 Limit 21 to (clinical trial, all or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative 
study or controlled clinical trial or randomized controlled trial)
361
23 Limit 22 to humans 353